Exploration of Neuroscience

Table 2

Clinical studies supporting the neuroprotective applications of triterpenoids

SN	Triterpenoid under study	Year	Condition	Type	Subjects	Duration	Findings	Ref
1	Ginsenoside Rd	2009	Acute ischemic stroke	Randomized, double-blind, placebo-controlled, phase 2, multicenter trial	199	14 days	Improvement in NIHSS score	[94] Clinical trial ID NCT00591084
2	Ginsenoside Rd	2012	Acute ischemic stroke	Randomized, double-blind, placebo-controlled, phase 3, multicenter trial	390	14 days	Improvement in primary outcome of acute ischaemic stroke Acceptable adverse-event profile	[93] Clinical trial ID NCT00815763
3	Centella asiatica selected triterpenes (CAST)	2022	Diabetic neuropathy	Randomized, double-blind, placebo-controlled, phase 2, trial	43	52 weeks	Reduced severity of symptoms	[96] Clinical trial ID NCT00608439
4	Licorice whole extract	2016	Acute ischemic stroke	Randomized, double-blind, placebo-controlled, phase 2, trial	75	7 days	Improvement in NIHSS score	[95] Clinical trial ID NCT02473458
5	Bacopa monnieri extract	2017	Healthy	Randomized, double-blind, placebo-controlled, phase 1, trial	75	16 weeks	NA	Clinical trial ID NCT02931747
6	Bacopa monnieri extract	2007	Schizophrenia	Randomized, open label, phase 2, trial	200	4 weeks	NA	Clinical trial ID NCT00483964

SN: serial number; NIHSS: National Institute of Health stroke scale; NA: not available